High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody
High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody
复制标题
DOI：
10.1093/brain/aww054
复制
发表时间：
2016-08-01
期刊：
影响因子：
14.5
通讯作者：
Benveniste, Olivier
中科院分区：
文献类型：
--
作者：
Allenbach, Yves;Keraen, Jeremy;Benveniste, Olivier
皮肌炎经常发生癌症，是导致死亡的主要原因。伊夫·阿伦巴赫等人。报道称，坏死性自身免疫性肌病患者患恶性肿瘤的风险也增加，肌炎特异性抗体可用于识别风险最大的患者。皮肌炎经常发生癌症，是导致死亡的主要原因。伊夫·阿伦巴赫等人。报告称，患有坏死性自身免疫性肌病的患者患恶性肿瘤的风险也增加，并且肌炎特异性抗体可用于识别风险最大的患者。患有炎症性肌病的患者可能会发生癌症。这种关联主要在皮肌炎中观察到，肌炎特异性抗体使我们能够确定风险增加的患者。据报道，坏死性自身免疫性肌病患者也会出现恶性肿瘤，但这种风险仍然难以捉摸。抗信号识别颗粒或抗 HMGCR 抗体与坏死性自身免疫性肌病特别相关。我们的目的是筛查坏死性自身免疫性肌病的癌症发病率。对一组患有坏死性自身免疫性肌病（有或没有肌炎特异性抗体）的患者（n = 115）进行了分析。与抗信号识别颗粒阳性患者相比，血清阴性坏死性自身免疫性肌病患者和 HMGCR 阳性患者中恶性肿瘤发生的频率更高。分别有 21.4% 和 11.5% 的病例被诊断出同时恶性肿瘤，且两组的癌症发病率均高于一般人群。没有特定类型的癌症占主导地位。患有同步癌症的患者的中位生存时间缩短。癌症筛查对于血清阴性坏死性自身免疫性肌病和 HMGCR 阳性患者是必要的，但对于抗信号识别颗粒阳性患者则不需要。
Cancer occurs frequently in dermatomyositis and is a major cause of mortality. Yves Allenbach et al. report that patients with necrotising auto-immune myopathies also have an increased risk of malignancy, and that myositis-specific antibodies can be used to identify those at greatest risk.Cancer occurs frequently in dermatomyositis and is a major cause of mortality. Yves Allenbach et al. report that patients with necrotising auto-immune myopathies also have an increased risk of malignancy, and that myositis-specific antibodies can be used to identify those at greatest risk.Cancer can occur in patients with inflammatory myopathies. This association is mainly observed in dermatomyositis, and myositis-specific antibodies have allowed us to delineate patients at an increased risk. Malignancy is also reported in patients with necrotizing autoimmune myopathies, but the risk remains elusive. Anti-signal recognition particle or anti-HMGCR antibodies have been specifically associated with necrotizing autoimmune myopathies. We aimed at screening the incidence of cancer in necrotizing autoimmune myopathies. A group of patients (n = 115) with necrotizing autoimmune myopathies with or without myositis-specific antibodies was analysed. Malignancy occurred more frequently in seronegative necrotizing autoimmune myopathies patients and in HMGCR-positive patients compared to anti-signal recognition particle positive patients. Synchronous malignancy was diagnosed in 21.4% and 11.5% of cases, respectively, and incidence of cancer was higher compared to the general population in both groups. No specific type of cancer was predominant. Patients suffering from a synchronous cancer had a decreased median survival time. Cancer screening is necessary in seronegative necrotizing autoimmune myopathies and in HMGCR-positive patients but not in anti-signal recognition particle-positive patients.